TRIPEP AB
35Patents
7Active
35Granted
38Portfolio score
Filing activity: Dec 27, 1996 → Nov 20, 2013 · 5 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6469143B2 | Antigen/antibody specificity exchanger | Emerging Cross-Sectional Technologies | 29 | Expired |
| US5869232A | Antigen/antibody specificity exchanger | Emerging Cross-Sectional Technologies | 20 | Expired |
| US6858590B2 | Vaccines containing ribavirin and methods of use thereof | Emerging Cross-Sectional Technologies | 19 | Expired |
| US6040137A | Antigen/antibody specification exchanger | Emerging Cross-Sectional Technologies | 17 | Expired |
| US6680059B2 | Vaccines containing ribavirin and methods of use thereof | Emerging Cross-Sectional Technologies | 17 | Expired |
| US6660842B1 | Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen | Emerging Cross-Sectional Technologies | 17 | Expired |
| US6417324B1 | Synthetic peptides that bind to the hepatitis B virus core and e antigens | Emerging Cross-Sectional Technologies | 15 | Expired |
| US6960569B2 | Hepatitis C virus non-structural NS3/4A fusion gene | Emerging Cross-Sectional Technologies | 14 | Expired |
| US6245895A | Antigen/antibody specificity exchanger | Emerging Cross-Sectional Technologies | 14 | Expired |
| US6258932A | Peptides that block viral infectivity and methods of use thereof | Emerging Cross-Sectional Technologies | 12 | Expired |
| US6933366B2 | Specificity exchangers that redirect antibodies to bacterial adhesion receptors | Emerging Cross-Sectional Technologies | 9 | Expired |
| US7022830B2 | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene | Emerging Cross-Sectional Technologies | 8 | Expired |
| US7226912B2 | Hepatitis C virus non-structural NS3/4A fusion gene | Emerging Cross-Sectional Technologies | 6 | Expired |
| US7307066B2 | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene | Emerging Cross-Sectional Technologies | 6 | Expired |
| US7223743B2 | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene | Emerging Cross-Sectional Technologies | 6 | Expired |
| US7439347B2 | Hepatitis C virus non-structural NS3/4A fusion gene | Emerging Cross-Sectional Technologies | 5 | Active |
| US7318926B2 | Glycosylated specificity exchangers | Chemistry; Metallurgy | 5 | Expired |
| US7332166B2 | Glycosylated specificity exchangers | Chemistry; Metallurgy | 4 | Expired |
| US9457183B2 | Injection needle and device | Chemistry; Metallurgy | 4 | Active |
| US7241440B2 | Vaccines containing ribavirin and methods of use thereof | Emerging Cross-Sectional Technologies | 4 | Expired |
| US7019111B2 | Glycosylated ligand/receptor specificity exchangers specific for bacterial adhesion receptors | Emerging Cross-Sectional Technologies | 3 | Expired |
| US7638499B2 | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene | Emerging Cross-Sectional Technologies | 3 | Active |
| US6455670B1 | Pentamer peptide amide, ALGPG-NH2, that inhibits viral infectivity and methods of use thereof | Chemistry; Metallurgy | 3 | Expired |
| US7012129B2 | Antiviral composition comprising glycine amide | Chemistry; Metallurgy | 3 | Expired |
| US7534435B2 | Glycosylated specificity exchangers | Chemistry; Metallurgy | 2 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.